Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Q4 and full-year results and provided an update on CAD-1005 for suspected heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 FDA meeting on March 26, 2026, reported Phase 2 data showing a >25% absolute reduction in thrombotic events, and is incorporating FDA feedback into a planned Phase 3 pivotal protocol.
Cadrenal held $4.0 million cash at December 31, 2025, reported a Q4 net loss of $3.0 million, and is evaluating financing and strategic alternatives to support clinical development.
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted research supporting its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, as a potential approach to reduce obesity- and Type 2 diabetes‑related inflammation. Preclinical oral dosing showed improved glycemic control, preserved pancreatic β-cells, fewer inflammatory cells in adipose and pancreas, and lower adipose pro-inflammatory cytokines. Cadrenal acquired the 12-LOX portfolio in December 2025 and reported Phase 2 results showing reduced thrombotic events in suspected HIT. The company is developing next-generation CAD-2000.
Cadrenal Therapeutics (Nasdaq: CVKD) expanded its pipeline with a portfolio of selective 12-LOX inhibitors, including oral candidates, and reported encouraging blinded Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia (HIT).
CAD-1005 showed a reduction in thrombotic events on standard anticoagulants and an End-of-Phase 2 (EOP-2) meeting is scheduled this month (March 2026). Management positions 12-LOX inhibition as a differentiated platform with potential acute and chronic applications across inflammatory and thrombotic diseases.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT) showing a >25% absolute reduction in thrombotic events versus placebo on top of standard anticoagulant therapy, despite no improvement in platelet count recovery. An End-of-Phase 2 FDA meeting is scheduled for March 2026 to align on a Phase 3 path. The trial was randomized, blinded, placebo-controlled and concluded in December 2025 after program transfer from Veralox. Detailed data will be presented at a future scientific meeting.
Cadrenal Therapeutics (NASDAQ: CVKD) highlighted the high incidence and clinical burden of thrombotic complications in heparin-induced thrombocytopenia (HIT) and promoted VLX-1005—acquired in December 2025—as the first highly selective 12-LOX inhibitor in clinical testing. Emerging Phase 2 data suggest VLX-1005 may reduce thrombotic complications in suspected HIT by targeting immune-driven platelet activation rather than only inhibiting coagulation.
VLX-1005 has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA; Cadrenal plans FDA discussions about a potential pivotal Phase 3 registration study. Cadrenal will also present at Lytham Partners on January 15, 2026.
Cadrenal Therapeutics (Nasdaq: CVKD) said management, including CEO Quang X. Pham, will hold partnering and investor meetings during the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026. The company highlighted two 2025 acquisitions and stated its focus on the $40 billion anticoagulation market.
Cadrenal's pipeline items cited: VLX-1005 (phase 2 IV 12-LOX inhibitor; ODD and Fast Track for HIT), tecarfarin (phase 3-ready oral VKA; ODD and Fast Track for ESKD with AFib; ODD for LVAD in collaboration with Abbott), and frunexian (phase 2-ready IV FXIa inhibitor for acute care).
Cadrenal Therapeutics (NASDAQ: CVKD) announced on Dec 11, 2025 the acquisition of VLX-1005 and related 12-LOX assets from Veralox Therapeutics, adding a late-stage, first-in-class small‑molecule 12‑lipoxygenase inhibitor for heparin‑induced thrombocytopenia (HIT).
VLX-1005 has U.S. Orphan Drug and Fast Track designations, completed two Phase 1 studies showing favorable tolerability, and interim Phase 2 data reporting reductions in thromboembolic events. The release cites a $40 billion global anticoagulation market and an estimated $1 billion HIT market in the US and EU. Veralox may receive upfront, milestone payments and royalties upon commercialization.
Cadrenal Therapeutics (Nasdaq: CVKD) announced on December 1, 2025 the immediate appointment of Lee Scott Golden, M.D., as an independent member of its Board of Directors. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics and has over 25 years of industry experience across cardiovascular and hematologic drug development.
His background includes senior medical roles at Espero BioPharma and Gemphire, leadership at Pfizer, Actelion, Eisai, and Mesoblast, and advisory work in coagulation sciences. Management highlighted his expertise in late-stage clinical development and regulatory pathways as aligned with Cadrenal’s goal to advance tecarfarin and its broader anticoagulation pipeline.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Q3 2025 results and clinical and corporate updates on November 10, 2025. Key development milestones include cGMP manufacturing completion for tecarfarin, ongoing activities supporting a single-site U.S. Phase 2 tecarfarin study in LVAD patients with Abbott, and investigator discussions for a potential multi-site Phase 2 dialysis study.
In September 2025 Cadrenal acquired eXIthera assets, adding a Phase 2-ready IV Factor XIa inhibitor, frunexian, aimed at acute care and device-related thrombosis settings. Q3 financials: R&D $0.7M, G&A $2.0M, net loss $2.7M, cash and equivalents $3.9M, and ~2.1M shares outstanding.
Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on anticoagulation therapy, will participate in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.
The company's webcast presentation is scheduled for 3:30 p.m. ET and will be accessible through the conference website. Management will also be available for one-on-one meetings with investors throughout the event.